HBK Sorce Advisory’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $694K | Sell |
4,494
-63
| -1% | -$9.44K | 0.01% | 320 |
|
|
2026
Q1 | $665K | Buy |
4,557
+195
| +4% | +$29.9K | 0.01% | 321 |
|
|
2025
Q4 | $682K | Buy |
4,362
+924
| +27% | +$121K | 0.02% | 301 |
|
|
2025
Q3 | $447K | Buy |
3,438
+329
| +11% | +$40.1K | 0.01% | 377 |
|
|
2025
Q2 | $376K | Buy |
3,109
+496
| +19% | +$55.9K | 0.01% | 404 |
|
|
2025
Q1 | $291K | Buy |
2,613
+272
| +12% | +$29K | 0.01% | 455 |
|
|
2024
Q4 | $228K | Buy |
2,341
+42
| +2% | +$4.48K | 0.01% | 514 |
|
|
2024
Q3 | $264K | Sell |
2,299
-222
| -9% | -$25.2K | 0.01% | 477 |
|
|
2024
Q2 | $268K | Buy |
2,521
+144
| +6% | +$14.5K | 0.01% | 467 |
|
|
2024
Q1 | $230K | Sell |
2,377
-62
| -3% | -$6.36K | 0.01% | 523 |
|
|
2023
Q4 | $246K | Buy |
2,439
+20
| +0.8% | +$1.93K | 0.01% | 461 |
|
|
2023
Q3 | $246K | Buy |
2,419
+24
| +1% | +$2.44K | 0.01% | 464 |
|
|
2023
Q2 | $242K | Buy |
2,395
+61
| +3% | +$6.1K | 0.01% | 493 |
|
|
2023
Q1 | $215K | Sell |
2,334
-2,454
| -51% | -$214K | 0.01% | 522 |
|
|
2022
Q4 | $434K | Buy |
+4,788
| New | +$403K | 0.01% | 441 |
|
|
2022
Q2 | – | Sell |
-2,320
| Closed | -$204K | – | 528 |
|
|
2022
Q1 | $204K | Sell |
2,320
-99
| -4% | -$8.57K | 0.01% | 509 |
|
|
2021
Q4 | $212K | Sell |
2,419
-3,105
| -56% | -$258K | 0.01% | 546 |
|
|
2021
Q3 | $452K | Sell |
5,524
-22
| -0.4% | -$1.98K | 0.02% | 336 |
|
|
2021
Q2 | $506K | Sell |
5,546
-189
| -3% | -$16.8K | 0.03% | 316 |
|
|
2021
Q1 | $490K | Buy |
5,735
+278
| +5% | +$24.9K | 0.03% | 304 |
|
|
2020
Q4 | $515K | Sell |
5,457
-598
| -10% | -$52.3K | 0.03% | 270 |
|
|
2020
Q3 | $527K | Sell |
6,055
-42
| -0.7% | -$3.64K | 0.04% | 249 |
|
|
2020
Q2 | $533K | Buy |
6,097
+1,155
| +23% | +$99.7K | 0.04% | 239 |
|
|
2020
Q1 | $407K | Buy |
4,942
+578
| +13% | +$51.6K | 0.04% | 238 |
|
|
2019
Q4 | $413K | Buy |
4,364
+908
| +26% | +$81.5K | 0.04% | 298 |
|
|
2019
Q3 | $300K | Buy |
3,456
+758
| +28% | +$68.1K | 0.03% | 324 |
|
|
2019
Q2 | $246K | Buy |
2,698
+366
| +16% | +$31K | 0.02% | 351 |
|
|
2019
Q1 | $201K | Buy |
+2,332
| New | +$187K | 0.02% | 408 |
|
|
2018
Q3 | – | Sell |
-5,062
| Closed | -$343K | – | 412 |
|
|
2018
Q2 | $343K | Buy |
+5,062
| New | +$349K | 0.04% | 283 |
|
Other funds holding NVS
HBK Sorce Advisory's NVS Position: Q2 2026 in Review
HBK Sorce Advisory reduced its Novartis (NVS) stake by 1.4% in Q2 2026, selling an estimated $9.44K and leaving 4,494 shares worth $694K. The position accounts for 0.01% of the portfolio, ranked #320.
HBK Sorce Advisory first reported a position in NVS in Q2 2018 and has held it in 29 quarters since. 1,625 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- HBK Sorce Advisory held 4,494 shares of Novartis worth $694K as of Q2 2026.
- HBK Sorce Advisory sold 63 Novartis shares in Q2 2026, an estimated $9.44K.
- Novartis made up 0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #320 holding.
- HBK Sorce Advisory first reported a position in Novartis in Q2 2018 and has held it in 29 quarters since.
- 1,625 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.